Phase Ib/II trial of NT219, an IRS1/2 and STAT3 inhibitor

This study evaluates fixed-dose NT219 combined with pembrolizumab or cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Conducted by University of Colorado, Denver, it enrolls HNSCC patients across multiple therapy lines, including those with prior PD-1/PD-L1 exposure, to assess the first-in-class inhibition of IRS1/2 and STAT3 in overcoming treatment resistance.